Abstract: Metastatic mucinous carcinomas in the ovary are readily recognized when they show characteristic features, including bilateral involvement, only moderate tumor size, surface and superficial cortical involvement, nodular growth, and an infiltrative pattern. However, it is well established that some metastatic mucinous carcinomas can simulate primary ovarian mucinous tumors grossly and microscopically. Metastatic pancreaticobiliary tract adenocarcinomas present a particular diagnostic challenge due to their ability to exhibit borderline-like and cystadenomatous growth patterns, which can be misinterpreted as underlying primary ovarian precursor tumors and can be erroneously used to support interpretation of the carcinomatous components as arising from these purported precursors within the ovary. Thirty-five cases of metastatic pancreaticobiliary tract adenocarcinomas were analyzed. The mean patient age was 58 years (median, 59 y; range, 33 to 78 y). In 15 cases (43%), the pancreaticobiliary tract and ovarian tumors presented synchronously and in 2 cases (6%) the ovarian tumors presented earlier as the first manifestation of the disease. Ovarian tumors were bilateral in 31 cases (89%). Mean and median tumor sizes were 10.6 and 9.5 cm, respectively (range, 2.5 to 21.0 cm). Nodularity was present in 22 cases (63%) and surface involvement was identified in 14 cases (40%). An infiltrative growth pattern was present at least focally in 28 cases (80%), accompanied by borderline-like and/or cystadenomatous areas in 17 (49%) cases and as the exclusive pattern in 11 cases (31%). Conversely, borderline-like and cystadenomatous patterns were identified in 24 cases (69%) and as the exclusive patterns (either pure or combined with one another) in 7 cases (20%). Dpc4 expression was lost in 20 of 33 tumors analyzed (61%). Of 25 patients with follow-up, 23 patients had died of disease (mean/median time, 9/6 mo; range, 1 to 39) and 2 patients were alive with disease (at 1 and 25 mo). Frequent bilateral ovarian involvement, moderate tumor size, nodularity, and infiltrative patterns are useful features for identifying these ovarian tumors as metastatic. However, many tumors exhibit borderline-like and cystadenomatous patterns that, when dominant and combined with synchronous presentation, make recognition as metastases an ongoing challenge. Loss of Dpc4 expression provides the most useful immunohistochemical evidence for establishing the pancreaticobiliary tract as the most likely source of these metastatic mucinous carcinomas in the ovary.
A mong ovarian epithelial tumors, the mucinous tumors pose the greatest difficulty with regard to distinction of primary from metastatic tumors. Metastatic mucinous carcinomas in the ovaries are usually easily distinguished from primary ovarian mucinous tumors, including atypical proliferative (borderline) tumors of gastrointestinal type and carcinomas, when they exhibit characteristic gross and microscopic features. Primary ovarian mucinous tumors are typically large, unilateral, multicystic tumors with smooth capsules and are most often unassociated with extraovarian disease. The primary ovarian mucinous carcinomas most often arise in association with atypical proliferative (borderline) tumors of gastrointestinal type. Although they can exhibit destructive stromal invasion, they frequently show a confluent glandular or expansile, rather than an infiltrative, pattern of invasion. In contrast, the typical features of metastatic mucinous carcinomas in the ovary that distinguish them from primary tumors include bilaterality, smaller size, ovarian surface and superficial cortical involvement, a nodular growth pattern, and an infiltrative pattern of stromal invasion. 9, 18, 20, 26, 32 However, some metastatic mucinous carcinomas can manifest 1 or more features suggesting a primary ovarian tumor both clinically and pathologically. These include presentation as a large, unilateral, multicystic tumor lacking surface involvement, sometimes as the first manifestation of disease in setting of a clinically occult extraovarian source, and certain Yes (omentum, cul-de-sac, fallopian tube) DOD 5 *The specific site of origin within the pancreaticobiliary tract could not be determined for 7 cases. wFollow-up has been calculated using the time of diagnosis of metastatic ovarian disease as the initial time point since in many cases the tumors were diagnosed synchronously and date of diagnosis of the primary tumor was not available for many of the asynchronous cases.
AWD indicates alive with disease; DOD, death due to disease; NA, not available. ability of these metastases to simulate primary ovarian tumors and recent studies providing refined diagnostic criteria for ovarian mucinous tumors 17, 18, 20, 21 , the problem of distinguishing these tumors persists. This problem is compounded by the fact that in routine practice, metastatic mucinous carcinomas are more common than primary ovarian mucinous carcinomas, with those of gastrointestinal and pancreaticobiliary tract origin being the most commonly encountered types. 26, 32 Metastatic pancreaticobiliary tract tumors with mucinous morphology account for nearly 14% of all metastatic mucinous tumors in the ovary. 32 They are typically pancreatic ductal adenocarcinomas but other pancreatic tumors such as acinar cell carcinomas have been observed. 27 Metastases from the biliary tract have also been documented, but these are less common than their pancreatic counterparts. 13, 14, 34 This study summarizes the clinicopathologic features of a large series of metastatic pancreaticobiliary tract adenocarcinomas in the ovaries, with emphasis on the ability of these tumors to exhibit features simulating primary ovarian mucinous tumors.
MATERIALS AND METHODS
The surgical pathology and consultation files of the Johns Hopkins Hospital were searched for all potential metastatic pancreaticobiliary tract (pancreas, gallbladder, distal common bile duct, and ampulla of Vater) tumors in the ovary, and slides from all available cases were retrieved for review. Electronic patient records (clinical records, reports of imaging studies) and pathology reports were reviewed as well. As the focus of this analysis was on the clinicopathologic features of the ovarian metastases, cases were included even when a pathologic specimen (cytologic or histologic) was not available from the pancreaticobiliary tract tumor, provided the ovarian metastasis was morphologically consistent with a pancreaticobiliary tract primary tumor (see below). In addition, at least 1 of the following was also required to provide support for a diagnosis of metastatic pancreaticobiliary tract adenocarcinoma: (1) imaging studies and/or intraoperative findings documenting the presence of a pancreaticobiliary tract mass, (2) presence of bilateral ovarian tumors, (3) presence of a nodular growth pattern within the ovarian tumor, (4) a documented history of pancreatic cancer or mass, or (5) loss of Dpc4 expression in the ovarian tumor. Primary pancreatic adenocarcinomas are typically characterized by glands recapitulating pancreatic ducts embedded in a desmoplastic stroma, often with some degree of mucinous differentiation and some having incomplete lumina. The nuclei are of variable shape and size, with distinct nucleoli and loss of polarity. Primary gallbladder and biliary tract adenocarcinomas are typically characterized by tubular glands lined by cuboidal or columnar cells resembling biliary epithelium, often with intracellular mucin. 8 Thus, adenocarcinomas in the ovary with similar features were considered morphologically consistent with adenocarcinomas of pancreaticobiliary tract origin. In addition, the literature showing the morphologic spectrum of metastatic pancreaticobiliary tract adenocarcinomas in the ovaries 13, 14, 33, 34 and our own experiences with established cases were used to assess tumors as having a morphology consistent with such origin. A total of 35 cases was identified. Of these, 16 were routine in-house cases and 19 were consultation cases.
Tumor size (of the largest ovary for bilateral tumors) and laterality data were extracted from pathology reports. For cases in which the status of 1 ovary could not be confirmed pathologically (status was not documented in any available pathology reports), the ovary was presumed to be negative unless there was intraoperative evidence of involvement, in which case the tumor was classified as bilateral. For cases in which pathologic specimens were available for both of the ovaries, tumors were classified as bilateral or unilateral based on the final pathologic diagnosis rather than only the intraoperative surgical or gross pathology findings.
Statistical analysis was performed using Microsoft Excel (Redmond, WA).
For descriptive purposes, the architectural growth patterns of the tumors were assessed as cystadenomatous, borderline-like, confluent glandular, or infiltrative, based on their resemblance to these types of patterns seen in primary ovarian mucinous tumors. 9, 23 Cytologic atypia was assessed as mild, moderate, or marked. Additional pathologic features that were assessed included the presence of surface involvement, nodular growth, extracellular mucin, and signet ring cells.
Immunohistochemical assessment of Dpc4 expression was performed on 5-mm deparaffinized tissue sections from 33 cases. The Dpc4 protocol at our institution was modified several times over the time period during which the cases were encountered. For all staining protocols, the same anti-Dpc4 antibody was used (clone B8; Santa Cruz Biotechnology, Santa Cruz, CA). Before 2004, reactions were carried out using the Ventana BioTek-Mate 1000 automated stainer (Ventana-BioTek Solutions, Tucson, AZ); antigen retrieval was performed using 1 Â sodium citrate buffer (diluted from 10 Â heat-induced epitope retrieval buffer) for 20 minutes at 801C before incubation with a prediluted anti-Dpc4 antibody (dilution 1:100). From 2004 to 2006, reactions were carried out using the A B FIGURE 3. This example of metastatic pancreaticobiliary tract carcinoma in the ovary exhibits borderline-like (A) and cystadenomatous (B) growth patterns, which were immediately adjacent to one another and extensive, simulating a primary ovarian atypical proliferative (borderline) mucinous tumor arising from a mucinous cystadenoma.
Dako Autostainer (Dako, Carpinteria, CA); antigen retrieval was performed using an Antigen Unmasking Solution (dilution 1:100; Vector Laboratories, Burlingame, CA) for 20 minutes at 951C before incubation with anti-Dpc4 antibody (dilution 1:500). From 2007 onwards, reactions were carried out using the BondMax Autostainer (Leica Microsystems, Bannockburn, IL); the sections were treated with a heat-induced epitope retrieval buffer for 20 minutes before incubation with anti-Dpc4 antibody (dilution 1:500). Secondary antibody application was followed by incubation with biotin-free polymer detection and 3,3-diaminobenzidine as the chromogen. The sections were counterstained with hematoxylin. Positive and negative controls were evaluated with each batch of reactions to ensure the quality of staining.
RESULTS
Thirty-five cases were reviewed. Nineteen cases were consultation cases sent for review to determine whether the ovarian tumors were metastatic versus independent primary ovarian tumors. Clinicopathologic features are summarized in Tables 1 and 2 . The mean patient age was 58 years (median, 59 y; range, 33 to 78 y). In 15 cases (43%), the pancreaticobiliary tract and ovarian tumors presented synchronously. For these cases, the most common clinical presentation was abdominal pain, followed by a pelvic, ovarian, or abdominal mass. In 20 cases (57%), the tumors presented asynchronously, with the pancreatic tumor diagnosis preceding the ovarian tumor diagnosis in 18 of these cases. The exact time interval between the diagnosis of the pancreaticobiliary tract tumor and the diagnosis of the ovarian metastases was known for 8 asynchronous cases. For the 6 cases with the pancreatic tumor diagnosis established first, the mean time interval to diagnosis of the ovarian metastases was 31 months (median, 27 mo; range, 2 to 92 mo). In the remainder, there were insufficient data to establish the time interval between diagnosis of the pancreaticobiliary tract and ovarian tumors. In 2 cases, the ovarian tumor presented first. In 1 of these, the clinical presentation was abdominal pain and the pancreaticobiliary tract tumor was diagnosed just over 1 month after the ovarian tumor. In the other case, the clinical presentation was as an ovarian mass, thought to be ovarian cancer clinically, and the pancreaticobiliary tract tumor was diagnosed 17 months after the ovarian tumor. The specific primary site within the pancreaticobiliary tract was assessed as pancreas in 22 (63%) cases, gallbladder in 4 (11%) cases, ampulla of Vater in 1 (3%) case, distal common bile duct A B in 1 (3%) case, and not specifically determined in the remaining 7 (20%) cases. Slides were available for review from at least 1 ovary in all 35 cases. Slides of both the ovaries were available for review in 18 cases, but pathology reports documented the status of both the ovaries in 30 cases. Specifically, there were 5 cases in which only 1 ovary was submitted as part of the pathologic specimens. In 1 of these, the ovary was deemed to be clinically positive but not removed. Therefore, this case was considered to be bilaterally involved. In another case, the ovary was assessed as clinically/surgically uninvolved. Therefore, this case was considered to be unilaterally involved. In the remaining 3 cases, the contralateral ovaries were of unknown status; so these were classified as unknown laterality. Metastases were thus assessed as bilateral in 31 (89%) of the 35 cases overall but pathologically confirmed as bilateral in 30 cases (86%). Most tumors had a cystic component or were both solid and cystic with mucinous contents. Using the size of the larger ovarian tumor in each case, the mean and median sizes were 10.6 and 9.5 cm, respectively (range, 2.5 to 21.0 cm).
The microscopic features of the ovarian tumors are detailed in Table 2 and illustrated in Figures 1 to 9 . Surface involvement was identified in 14 cases (40%), was absent in 10 cases (29%), and could not be definitively determined in the remaining cases (due to lack of specific gross description regarding this and lack of evidence of definitive ovarian surface on available slides). A nodular growth pattern was present in 22 cases (63%), with nodules often present in the superficial cortex and sometimes accompanied by surface involvement (Fig. 1) . In most cases, the growth patterns of the tumors were admixed within a given ovary. These patterns were typically similar in bilaterally involved ovaries, but occasionally the patterns in the paired ovaries were different (for details see Table 2 ). An infiltrative growth pattern was present at least focally in 28 cases (80%) (Fig. 2) , accompanied by borderline-like and/or cystadenomatous areas in 17 cases (49%), and as the exclusive pattern in 11 cases (31%). Conversely, borderline-like and/or cystadenomatous patterns were identified in 24 cases (69%) overall and as the exclusive patterns (either pure or combined with one another) in 7 cases (20%) (Fig. 3) . More specifically, a borderline-like growth pattern was present in 19 cases (54%); this pattern was exclusive in 4 cases (11%). In particular, those tumors exhibiting extensive borderline-like growth patterns were characterized by multiple cysts and glands of various sizes, papillary infoldings, and nuclear stratification, without evident stromal invasion (Fig. 4) . Those tumors with marked atypia simulated atypical proliferative (borderline) tumors with intraepithelial carcinoma (Fig.  5) . Those with small infiltrative foci adjacent to the borderline-like areas simulated atypical proliferative (borderline) tumors with microinvasive carcinoma (Fig. 6) . A cystadenomatous growth pattern was present in 16 cases (46%) (Fig. 3) . This pattern was exclusive in 2 cases (6%). Of note, the 1 case in which the ovarian tumor was diagnosed approximately 1 month before the pancreaticobiliary tract tumor was initially interpreted as a primary ovarian atypical proliferative (borderline) mucinous tumor based on its exclusively borderline-like growth pattern. This tumor was clinically and grossly unilateral but a microscopic focus of tumor (rare atypical glands) was found in the contralateral ovary. Thus, it was considered to be microscopically bilateral. Metastatic mucinous carcinoma was found in the omentum; thus the tumor was classified as an "advanced-stage mucinous borderline tumor." It was only reassessed as metastatic pancreatic adenocarcinoma after a fine needle aspiration biopsy confirmed a diagnosis of primary pancreatic carcinoma and consultation in our laboratory established loss of Dpc4 expression in both the pancreatic and ovarian tumors. In the other case in which the ovarian tumor was diagnosed before the pancreaticobiliary tract tumor (17 mo earlier), the ovarian tumor had been diagnosed as mucinous carcinoma that was thought to be consistent with ovarian origin; however, a comment was made that the possibility of a metastasis from the gastrointestinal tract could not be excluded.
Cytologic atypia was quite variable in most tumors, ranging from mild to marked in most of them (Fig. 7) . All tumors showed at least moderate atypia in some areas; most commonly (approximately 90% of cases), the maximum degree of atypia was marked. Nine tumors (26%) showed a secretory-like change in the glands, characterized by distinctive cytoplasmic vacuolization (Fig. 8) , as has been previously recognized. 1 Two tumors (6%) exhibited a "colloid carcinoma-like" pattern, characterized by small fragments of carcinomatous mucinous epithelium suspended within pools of extracellular mucin (Fig. 8) . Dpc4 expression was lost in 20 tumors (61%; Fig. 9 ), was retained in 13 tumors (39%), and was not determined in the remaining 2 tumors.
Extraovarian disease was documented in 34 cases. Follow-up data are presented in Table 1 . Of 25 patients with follow-up, 23 patients had died of disease (mean/ median time, 9/6 mo; range, 1 to 39 mo), and 2 patients were alive with disease (at 1 and 25 mo). B A FIGURE 6. Examples of metastatic pancreaticobiliary tract carcinoma in the ovary simulate primary ovarian atypical proliferative (borderline) mucinous tumors with microinvasive carcinoma. In 1 tumor (A), a small region of infiltrative nests is adjacent to borderline-like tumor with focal intraglandular cribriform architecture. In another tumor (B), a small region of infiltrative fused glandular epithelium is adjacent to well-differentiated glands exhibiting a borderline-like growth pattern.
DISCUSSION
This study represents the largest series of metastatic pancreaticobiliary tract adenocarcinomas in the ovary reported to date. As recognized in prior studies, these tumors are notorious for their ability to simulate primary ovarian mucinous tumors. 13, 14, 33, 34 In particular, metastatic pancreaticobiliary tract adenocarcinomas present a particular diagnostic challenge because of their ability to exhibit borderline-like and cystadenomatous growth patterns, simulating these types of primary ovarian mucinous tumors. When admixed with a carcinomatous component, these growth patterns can be misinterpreted as underlying primary ovarian precursor tumors and thereby can be erroneously used to support interpretation of the carcinomatous component as arising from these purported precursors within the ovary. 33, 34 In some cases, these patterns can be so dominant or exclusive that the tumor is interpreted as an atypical proliferative (borderline) tumor with microinvasion/microinvasive carcinoma (when only small invasive foci are identified) or with only intraepithelial carcinoma (when only marked cytologic atypia, without evidence of destructive stromal invasion, is identified). This problem is compounded by the not infrequent presentation of these ovarian metastases synchronously with, or even before, the pancreaticobiliary tract mass, raising the question of independent neoplasms in the former situation and making recognition as metastatic tumor exceedingly difficult in the latter. This study confirms these findings by showing that synchronous presentation is common (43%) and that tumors frequently exhibit borderline-like and cystadenomatous patterns (69%).
One of the cases encountered in this study provides a clear example to support the notion that a subset of the so-called mucinous "borderline"/"low malignant potential" tumors, particularly those with "intraepithelial carcinoma" and/or "microinvasion," with adverse outcomes reported in the older literature likely represents A B C D FIGURE 7 . Several examples illustrate the spectrum of cytologic atypia and architectural diversity of metastatic pancreaticobiliary tract carcinomas in the ovary. Cystadenomatous areas exhibit essentially no nuclear atypia (A). Borderline-like areas show a spectrum of nuclear atypia ranging from mild to marked (B). Well-formed glands in an infiltrative tumor demonstrate moderatemarked nuclear atypia (C). Poorly differentiated areas in an infiltrative tumor manifest marked nuclear atypia with pleomorphism (D).
Am J Surg Pathol Volume 35, Number 2, February 2011 Ovarian Metastases of Pancreaticobiliary Tract Carcinomas misclassified metastatic mucinous carcinomas from clinically occult primary tumors arising elsewhere. In the absence of subsequent clinical investigation and consultation, this ovarian mucinous tumor (described in Results), which represented the initial manifestation of disease, would have been erroneously classified as an "advancedstage mucinous borderline tumor" with evolution to carcinoma and eventual adverse outcome. Such examples have been cited to justify the retention of the designation "borderline" for this group of ovarian mucinous tumors. However, recent studies have refined the diagnostic criteria for ovarian mucinous tumors and the recognition of metastatic mucinous carcinomas in the ovaries. 17, 18, 20, 21, 23 The modern literature on well-sampled primary ovarian mucinous tumors qualifying as borderline and lacking both intraepithelial and microinvasive carcinoma based on rigorously applied more recently established criteria shows that these ovarian tumors are essentially all stage I tumors without adverse outcomes. 4, 23 In addition, studies on metastatic mucinous carcinomas have drawn attention to the ability of metastases to simulate primary ovarian mucinous tumors and have improved the recognition of these tumors, especially those with deceptive patterns of invasion, thereby reducing their misclassification as primary ovarian tumors. 6, 7, 9, 10, 12, 16, [18] [19] [20] [22] [23] [24] 26, 28, [32] [33] [34] These observations form the basis for advocating the use of the morphologically and clinically more meaningful term "atypical proliferative mucinous tumor" for this group of primary ovarian mucinous tumors. 15 Fortunately, these metastatic pancreaticobiliary tract adenocarcinomas in the ovaries are commonly bilateral (89%), only moderately enlarged (mean/median size <12 cm), and frequently nodular (63%). These features have been established as useful for confirming that mucinous tumors in the ovary are likely to be metastatic. 18, 32 Application of a recently proposed modified algorithm for the classification of mucinous tumors in the ovary as primary versus metastatic based on size and laterality criteria 32 would have led to the correct classification of 100% of the 31 tumors with known laterality and/or size. Although using bilaterality as 1 of the criteria for including cases without a pathologically documented primary tumor can introduce some bias that could affect the frequency of bilaterality in the study, we believe that this effect is probably minimal. With rare exceptions, the included cases without a pathologically documented primary tumor were accepted on the basis of the presence of at least 2 of the inclusion criteria and the few candidate cases that were excluded were rejected on B A the basis of various pathologic factors rather than unilaterality alone (detailed results not shown).
The few readily available immunohistochemical markers for distinguishing primary and metastatic mucinous tumors in the ovaries, such as cytokeratin 7, cytokeratin 20, and CDX2, have limited value in distinguishing primary ovarian mucinous tumors from metastatic pancreaticobiliary tract adenocarcinomas due to shared expression patterns between these tumors. 29, 30 A few studies have shown the value of immunohistochemical analysis of Dpc4 expression in this distinction. 3, 11 DPC4 encodes a nuclear transcription factor and tumor suppressor gene on chromosome 18q and is genetically inactivated by allelic loss in approximately 55% of pancreatic ductal adenocarcinomas and in 10% to 50% of biliary tract adenocarcinomas, 2, 5, 28 but only rarely in adenocarcinomas of other sites. 25, 31 Loss of expression of the DPC4 gene product (Dpc4) assessed by immunohistochemistry is sensitive and specific for DPC4 gene alteration, thus providing a simple test for DPC4 gene status in archival material. 31 Consequently, loss of Dpc4 expression is useful for incriminating the pancreaticobiliary tract as the source of a metastatic mucinous adenocarcinoma in the ovary because primary ovarian mucinous tumors have not been shown to exhibit loss of expression. This study confirms this utility and the frequency of expression that has been observed before in both primary pancreaticobiliary tumors and ovarian metastases by showing loss of Dpc4 expression in 61% of the ovarian metastases analyzed herein. Of note, retained expression of this marker neither confirms nor refutes a diagnosis of metastatic pancreaticobiliary tract adenocarcinoma, as 39% of these metastases retained expression. This latter subset is currently diagnosed on the basis of traditional clinicopathologic features because other markers for distinguishing primary ovarian mucinous tumors from metastatic pancreaticobiliary tract adenocarcinomas are lacking.
